The promise and perils of weight loss drugs
Doctors have warned of the risk of overuse and misuse, cautioning that patients will see such medications as an easy, quick fix,…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Wegovy
Heart failure market to grow at 9.6 per cent CAGR in 7MM during 2022-32
GlobalData’s report reveals that the US will contribute the most to the growth of the HF market due to the higher prevalence of HF…
Eli Lilly’s Zepbound holds possibility to dominate obesity market
Recently, Eli Lilly announced the results from its SURMOUNT-5 trial, comparing Zepbound and Wegovy’s efficacy on equal grounds
PCRM survey shows that most Americans don’t prefer new weight-loss drugs
The survey included 2,205 adults and was conducted on September 5, 2024
Novo Nordisk to launch weight-loss drug Wegovy in Australia this month
The drug will not be subsidised under the Pharmaceutical Benefits Scheme
Novo Nordisk’s Wegovy gets MHRA nod for use to lower heart risks
Semaglutide is the first weight loss drug approved in the UK as a preventative treatment for those with established cardiovascular…
GLP-1R agonists clinical trial design needs to be improved to reassure drugs’ benefits: GlobalData
According to GlobalData, there are over 50 clinical trials for type 2 diabetes or obesity treatment involving GLP-1R agonists
GLP1 agonists set to become the best-selling drugs in 2024: GlobalData
Shift could reflect a changing demand away from oncology toward addressing metabolic disorders
Top 20 global biopharma companies report 1.6 per cent per cent market cap growth to $3.67 tn in…
Four companies – Lilly (59.2 per cent), Novo Nordisk (51.5 per cent), Vertex Pharmaceuticals (41.4 per cent) and Regeneron…
Catalent to help Novo Nordisk address production demands for Ozempic and Wegovy: GlobalData
The acquisition of Catalent by Novo Holdings expects to see three new manufacturing sites added to Novo Nordisk’s arsenal, to…